vs

Side-by-side financial comparison of Trade Desk (The) (TTD) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

DENTSPLY SIRONA Inc. is the larger business by last-quarter revenue ($961.0M vs $846.8M, roughly 1.1× Trade Desk (The)). Trade Desk (The) runs the higher net margin — 22.1% vs -15.2%, a 37.3% gap on every dollar of revenue. On growth, Trade Desk (The) posted the faster year-over-year revenue change (14.3% vs 6.2%). Trade Desk (The) produced more free cash flow last quarter ($285.3M vs $60.0M). Over the past eight quarters, Trade Desk (The)'s revenue compounded faster (31.3% CAGR vs 0.4%).

The Trade Desk, Inc. is an American multinational technology company that specializes in real-time programmatic marketing automation technologies, products, and services, designed to personalize digital content delivery to users.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

TTD vs XRAY — Head-to-Head

Bigger by revenue
XRAY
XRAY
1.1× larger
XRAY
$961.0M
$846.8M
TTD
Growing faster (revenue YoY)
TTD
TTD
+8.1% gap
TTD
14.3%
6.2%
XRAY
Higher net margin
TTD
TTD
37.3% more per $
TTD
22.1%
-15.2%
XRAY
More free cash flow
TTD
TTD
$225.3M more FCF
TTD
$285.3M
$60.0M
XRAY
Faster 2-yr revenue CAGR
TTD
TTD
Annualised
TTD
31.3%
0.4%
XRAY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
TTD
TTD
XRAY
XRAY
Revenue
$846.8M
$961.0M
Net Profit
$186.9M
$-146.0M
Gross Margin
80.7%
46.1%
Operating Margin
30.3%
-14.5%
Net Margin
22.1%
-15.2%
Revenue YoY
14.3%
6.2%
Net Profit YoY
2.6%
66.0%
EPS (diluted)
$0.39
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TTD
TTD
XRAY
XRAY
Q4 25
$846.8M
$961.0M
Q3 25
$739.4M
$904.0M
Q2 25
$694.0M
$936.0M
Q1 25
$616.0M
$879.0M
Q4 24
$741.0M
$905.0M
Q3 24
$628.0M
$951.0M
Q2 24
$584.5M
$984.0M
Q1 24
$491.3M
$953.0M
Net Profit
TTD
TTD
XRAY
XRAY
Q4 25
$186.9M
$-146.0M
Q3 25
$115.5M
$-427.0M
Q2 25
$90.1M
$-45.0M
Q1 25
$50.7M
$20.0M
Q4 24
$182.2M
$-430.0M
Q3 24
$94.2M
$-494.0M
Q2 24
$85.0M
$-4.0M
Q1 24
$31.7M
$18.0M
Gross Margin
TTD
TTD
XRAY
XRAY
Q4 25
80.7%
46.1%
Q3 25
78.1%
48.8%
Q2 25
78.2%
52.4%
Q1 25
76.8%
53.0%
Q4 24
81.7%
49.3%
Q3 24
80.5%
52.1%
Q2 24
81.1%
51.9%
Q1 24
78.9%
53.1%
Operating Margin
TTD
TTD
XRAY
XRAY
Q4 25
30.3%
-14.5%
Q3 25
21.8%
-24.1%
Q2 25
16.8%
-13.7%
Q1 25
8.8%
7.2%
Q4 24
26.4%
-56.2%
Q3 24
17.3%
-48.6%
Q2 24
16.2%
5.1%
Q1 24
5.8%
4.4%
Net Margin
TTD
TTD
XRAY
XRAY
Q4 25
22.1%
-15.2%
Q3 25
15.6%
-47.2%
Q2 25
13.0%
-4.8%
Q1 25
8.2%
2.3%
Q4 24
24.6%
-47.5%
Q3 24
15.0%
-51.9%
Q2 24
14.5%
-0.4%
Q1 24
6.4%
1.9%
EPS (diluted)
TTD
TTD
XRAY
XRAY
Q4 25
$0.39
$-0.74
Q3 25
$0.23
$-2.14
Q2 25
$0.18
$-0.22
Q1 25
$0.10
$0.10
Q4 24
$0.36
$-2.09
Q3 24
$0.19
$-2.46
Q2 24
$0.17
$-0.02
Q1 24
$0.06
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TTD
TTD
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$1.3B
$326.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$2.5B
$1.3B
Total Assets
$6.2B
$5.4B
Debt / EquityLower = less leverage
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TTD
TTD
XRAY
XRAY
Q4 25
$1.3B
$326.0M
Q3 25
$1.4B
$363.0M
Q2 25
$1.7B
$359.0M
Q1 25
$1.7B
$398.0M
Q4 24
$1.9B
$272.0M
Q3 24
$1.7B
$296.0M
Q2 24
$1.5B
$279.0M
Q1 24
$1.4B
$291.0M
Total Debt
TTD
TTD
XRAY
XRAY
Q4 25
$2.3B
Q3 25
Q2 25
Q1 25
Q4 24
$1.7B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
TTD
TTD
XRAY
XRAY
Q4 25
$2.5B
$1.3B
Q3 25
$2.6B
$1.5B
Q2 25
$2.7B
$2.0B
Q1 25
$2.7B
$2.0B
Q4 24
$2.9B
$1.9B
Q3 24
$2.6B
$2.5B
Q2 24
$2.4B
$3.1B
Q1 24
$2.2B
$3.3B
Total Assets
TTD
TTD
XRAY
XRAY
Q4 25
$6.2B
$5.4B
Q3 25
$5.9B
$5.7B
Q2 25
$6.0B
$6.1B
Q1 25
$5.7B
$6.0B
Q4 24
$6.1B
$5.8B
Q3 24
$5.5B
$6.6B
Q2 24
$5.2B
$6.9B
Q1 24
$4.7B
$7.1B
Debt / Equity
TTD
TTD
XRAY
XRAY
Q4 25
1.70×
Q3 25
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TTD
TTD
XRAY
XRAY
Operating Cash FlowLast quarter
$311.6M
$101.0M
Free Cash FlowOCF − Capex
$285.3M
$60.0M
FCF MarginFCF / Revenue
33.7%
6.2%
Capex IntensityCapex / Revenue
3.1%
4.3%
Cash ConversionOCF / Net Profit
1.67×
TTM Free Cash FlowTrailing 4 quarters
$795.7M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TTD
TTD
XRAY
XRAY
Q4 25
$311.6M
$101.0M
Q3 25
$224.7M
$79.0M
Q2 25
$165.0M
$48.0M
Q1 25
$291.4M
$7.0M
Q4 24
$199.4M
$87.0M
Q3 24
$273.3M
$141.0M
Q2 24
$81.3M
$208.0M
Q1 24
$185.5M
$25.0M
Free Cash Flow
TTD
TTD
XRAY
XRAY
Q4 25
$285.3M
$60.0M
Q3 25
$158.3M
$40.0M
Q2 25
$119.8M
$16.0M
Q1 25
$232.3M
$-12.0M
Q4 24
$179.2M
$36.0M
Q3 24
$224.6M
$98.0M
Q2 24
$59.1M
$156.0M
Q1 24
$178.2M
$-9.0M
FCF Margin
TTD
TTD
XRAY
XRAY
Q4 25
33.7%
6.2%
Q3 25
21.4%
4.4%
Q2 25
17.3%
1.7%
Q1 25
37.7%
-1.4%
Q4 24
24.2%
4.0%
Q3 24
35.8%
10.3%
Q2 24
10.1%
15.9%
Q1 24
36.3%
-0.9%
Capex Intensity
TTD
TTD
XRAY
XRAY
Q4 25
3.1%
4.3%
Q3 25
9.0%
4.3%
Q2 25
6.5%
3.4%
Q1 25
9.6%
2.2%
Q4 24
2.7%
5.6%
Q3 24
7.8%
4.5%
Q2 24
3.8%
5.3%
Q1 24
1.5%
3.6%
Cash Conversion
TTD
TTD
XRAY
XRAY
Q4 25
1.67×
Q3 25
1.94×
Q2 25
1.83×
Q1 25
5.75×
0.35×
Q4 24
1.09×
Q3 24
2.90×
Q2 24
0.96×
Q1 24
5.86×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TTD
TTD

Other$427.2M50%
Non Us$419.6M50%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons